Novo Nordisk cuts Wegovy prices in India up to 37% and faces a pivotal board vote this week, as a U.S. pricing/access deal looms for 2026.
Date: November 11, 2025
Key takeaways
- India price cut: Novo Nordisk reduced the monthly price of Wegovy across dose strengths in India—as low as ₹10,850 for 0.25 mg and ₹16,400 for 2.4 mg—a reduction of up to 37% from launch pricing. The move sharpens its response to Eli Lilly’s surging Mounjaro.
- Competitive context: Mounjaro became India’s top‑selling drug by value in October, underlining the intensity of the GLP‑1 battle.
- U.S. access & pricing: Novo announced a U.S. Administration agreement to lower semaglutide prices and enable Medicare Part D pilot coverage for anti‑obesity medicines beginning in 2026; the Medicare‑negotiated price for semaglutide under the IRA framework is slated to take effect in 2027.
- Governance in focus: An Extraordinary General Meeting (EGM) on Friday, Nov. 14, 2025 (14:00 CET) will elect a new board; Norway’s NBIM says it will abstain on key votes.
- Pipeline/clinical: New analyses presented at AASLD’s Liver Meeting suggest potential liver health–related benefits with semaglutide 2.4 mg in MASH beyond weight loss (company‑sponsored post hoc data).
India: Wegovy gets markedly cheaper — and it’s about more than price
Novo Nordisk cut Wegovy’s Indian list prices across the dose range, with the monthly 2.4 mg pack now at ₹16,400 (down from ₹24,389 at launch) and the 0.25 mg starter at ₹10,850 (from ₹16,260). The company confirmed the reductions amid a fast‑evolving obesity market in the country. Reuters updated its initial “up to 33%” reporting to note cuts “up to 37%” versus launch pricing, clarifying the magnitude of the change. Reuters+1
The price action lands as semaglutide’s Indian patent expires in March 2026, a milestone that could open the door to generics and increase price sensitivity further.
The India chessboard: POVIZTRA branding and Lilly’s momentum
On Nov. 10, Novo Nordisk said it will work with Emcure Pharmaceuticals to distribute a 2.4 mg semaglutide injection under the separate brand POVIZTRA, extending its reach beyond the Wegovy brand architecture. Pricing was not disclosed in that announcement.
The pressure is real: Eli Lilly’s Mounjaro became India’s top‑selling drug by value in October, reflecting how fast the GLP‑1 category is scaling in the market and why Novo is moving aggressively on price.
U.S. policy tailwinds: Access deal for 2026 and IRA price setting for 2027
Beyond India, Novo Nordisk announced on Nov. 6 that it reached an agreement with the U.S. Administration to lower prices for semaglutide (Wegovy/Ozempic) across Medicare Part D, Medicaid, and direct cash‑pay channels beginning in 2026, while enabling a Medicare Part D pilot for obesity medicines to expand coverage. Novo currently expects a low single‑digit negative impact on 2026 global sales growth as lower prices are offset by expanded access.
Separately, under the Inflation Reduction Act, Novo said on Nov. 5 it has agreed a Medicare price for semaglutide (effective 2027); analysts framed the outcome as less onerous than feared, even as the company trimmed guidance alongside Q3 results.
Governance watch: New board vote on Nov. 14 amid investor scrutiny
This Friday, Nov. 14, 2025, Novo Nordisk holds an EGM at 14:00 CET to elect a new board. The Novo Nordisk Foundation aims to install Lars Rebien Sørensen as chair, an arrangement that has drawn governance attention because he already chairs the Foundation. Norway’s sovereign wealth fund (NBIM) said it will abstain from voting on the chair and other nominees.
The governance backdrop follows Novo’s decision to withdraw from the bidding war for Metsera, which markets cheered as a reduced distraction and potential risk, according to reporting on Monday.
Insider transactions disclosed today
In a company announcement published Nov. 11, Novo disclosed recent transactions by executives and associated persons under EU Market Abuse rules. Notably, Executive Vice President (U.S. Operations) David Moore acquired 18,634 B‑shares at DKK 0 (as part of a recruitment package) and sold 8,160 shares at DKK 297.95 on Nov. 10, for an aggregate DKK 2.43 million.
Science & pipeline: New liver disease analyses for semaglutide 2.4 mg
At the AASLD Liver Meeting (Nov. 7–11), Novo presented post hoc analyses indicating that semaglutide 2.4 mg (Wegovy) in adults with MASH with fibrosis was associated with liver health–related benefits not solely dependent on weight loss. The data are exploratory and company‑sponsored; Novo notes semaglutide 2.4 mg carries accelerated approval in the U.S. for MASH with moderate‑to‑advanced fibrosis, with confirmatory evidence required.
Market context: Guidance resets and what investors are watching
Investor sentiment toward GLP‑1 leaders has whipsawed in recent weeks. Alongside the U.S. policy developments, Novo’s Q3 update (Nov. 5) showed lowered guidance and mixed volume trends for Wegovy and Ozempic, reflecting intensifying competition and pricing pressure.
What to watch next
- EGM outcome (Nov. 14, 2025): The board slate and chair vote will signal the corporate governance trajectory heading into 2026.
- U.S. access rollout (2026): Details of the Medicare Part D pilot for anti‑obesity medicines and how price/coverage changes alter U.S. demand and mix.
- India dynamics: Effect of the Wegovy price cut and POVIZTRA distribution on market share against Mounjaro—especially as semaglutide’s patent expiry in India (March 2026) approaches.
- Metsera aftermath: Post‑withdrawal capital allocation priorities, including manufacturing scale‑up and pipeline acceleration.
- Clinical milestones: Follow‑up readouts in MASH (ESSENCE program) and broader cardiometabolic endpoints that could expand GLP‑1 use cases.
Sources
- Reuters: India price cut (updated to up to 37% vs. launch; dose‑level rupee pricing; patent timing; competitive backdrop).
- Reuters: Mounjaro becomes India’s top‑selling drug by value (October).
- Reuters & Novo IR: U.S. IRA Medicare price agreement (effective 2027) and prior guidance cut; U.S. Administration pricing/access agreement and Medicare Part D pilot for 2026 (company announcement).
- Reuters & Novo investors page:EGM timing and NBIM abstention on board vote; shares rose after exiting Metsera bid.
- GlobeNewswire (Novo):Insider transactions disclosure (Nov. 11).
- PR Newswire (Novo):MASH post‑hoc analyses with semaglutide 2.4 mg (AASLD Liver Meeting).
- Reuters:POVIZTRA brand with Emcure in India (Nov. 10).
Disclosure: This article is for informational purposes only and does not constitute investment advice. Always verify company filings and official press releases before making financial decisions.
